infliksimabi

Infliximab, marketed under several brand names including Remicade, is a chimeric monoclonal antibody that targets tumor necrosis factor alpha (TNF-α). It is a biologic therapy administered by intravenous infusion in a clinical setting. After an induction course, maintenance infusions are given at intervals ranging from every 6 to 8 weeks, with dosing adjusted for body weight and the specific condition being treated.

Mechanism of action: Infliximab binds to soluble and transmembrane TNF-α, inhibiting its interaction with TNF receptors. This reduces inflammatory signaling and modulates immune activity associated with autoimmune and inflammatory diseases. Because it suppresses parts of the immune system, patients are monitored for infections and other immune-related effects.

Common indications: Infliximab is approved for several autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. It is also used in some pediatric contexts and in other inflammatory diseases according to regional approvals and guidelines.

Administration, monitoring, and safety: Prior to starting therapy, patients are typically screened for latent tuberculosis and hepatitis B due to infection risk. Antibodies against infliximab can develop in some patients, potentially reducing efficacy and increasing infusion reactions. Infusion-related reactions, infections (including serious or opportunistic infections), and rare but serious adverse events such as heart failure exacerbation, demyelinating disorders, and certain malignancies have been reported. Hepatosplenic T-cell lymphoma has been reported mainly in younger patients on concurrent immunosuppressants. Treatment decisions consider potential benefits, risks, and monitoring requirements.

Biosimilars exist and are used in many regions as alternatives to the original product.